In Brief: Medicare drug coverage
Executive Summary
Medicare drug coverage: Oral anti-nausea drugs will be covered by Medicare "for use immediately before, at, or within 48 hours" of cancer chemotherapy under a House/Senate conference agreement passed by the House July 30 and the Senate July 31. The conferees "expect the oral forms of the anti-emetics will result in substantial cost savings to Medicare" relative to I.V. versions, according to report language. The agreement deletes House provisions setting a per dose payment level equal to 90% of the average per dose payment basis for the equivalent I.V. anti-emetic...
You may also be interested in...
Part D Discount Liability Coming Into Focus: CMS Releases Drug Cost Data
Newly released Medicare Part D data sheds light on the sales hit that branded pharmaceutical manufacturers will face when the coverage gap discount program gets under way in 2011
FDA Skin Infections Guidance Spurs Debate On Endpoint Relevance
FDA appears headed for a showdown with clinicians and the pharmaceutical industry over the proposed new clinical trial endpoints for acute bacterial skin and skin structure infections, the guidance's approach for justifying a non-inferiority margin and proposed changes in the types of patients that should be enrolled in trials
Shire Hopes To Sow Future Deals With $50M Venture Fund
Specialty drug maker Shire has quietly begun scouting deals with a brand-new $50 million venture fund, the latest of several in-house investment arms to launch with their parent company's pipelines, not profits, as the measure of their worth